Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Director/PDMR Shareholding

1st Apr 2011 16:00

Director/PDMR Shareholding

April 1, 2011 - Shire plc , the global specialtybiopharmaceutical company (the "Company") announces that it was notified todaythat on March 31, 2011 the Ordinary Shares ("Shares") and American DepositoryShares ("ADSs") in the Company set out below had been awarded under theExecutive Annual Incentive Plan (the "Plan") to the Company's ExecutiveDirectors and Persons Discharging Managerial Responsibility ("PDMRs"). TheShares and ADSs were bought on the market on March 31, 2011 at prices of £18.23per Share and US$87.5077 per ADS. The awards are in respect of performance in2010.Name of Director Type of Number of Security Shares/ADSs purchased Angus Russell ADSs 3,994 Graham Hetherington Shares 6,504 Name of PDMR Type of Number of Shares/ADSs security purchased Michael Cola ADSs 2,068 Barbara Deptula ADSs 1,141 Sylvie Gregoire ADSs 2,139 Tatjana May Shares 4,450

Under the terms of the Plan, the awards will not normally be released to participants for three years. One ADS is equal to three Shares.

In addition, on April 1, 2011 the Company was notified of the release on March 31, 2011 of the Shares and ADSs awarded in 2008 under the Plan. These awards were in respect of performance in 2007. The ADSs below were awarded to Mr Emmens whilst he held the position of Chief Executive Officer of the Company.

In accordance with the rules of the Plan, the following Shares/ADSs werereleased:Name of Director Type of Number of Shares/ADSs Number of Shares/ADSs Security released sold to satisfy tax liabilities Matthew Emmens ADSs 12,881 4,345 Angus Russell Shares 20,068 5,715 Name of PDMR Type of Number of Shares/ADSs Number of Shares/ADSs security released sold to satisfy tax liabilities Michael Cola ADSs 3,528 1,377 Barbara Deptula ADSs 3,098 1,020 Sylvie Gregoire ADSs 790 321 Tatjana May Shares 11,019 5,635

Sufficient Shares or ADSs were sold to satisfy tax liabilities as set out above. Such Shares or ADSs were sold on March 31, 2011, at prices of £18.1818 per Share and $87.1826 per ADS.

This notification is made to satisfy the Company's obligations under 3.1.4(R) (1)(a) of the Disclosure and Transparency Rules.

Tony GuthrieDeputy Company Secretary

For further information please contact:

Investor Relations Eric Rojas erojas@shire.com +1 781 482 0999 Notes to editorsSHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: www.shire.com.

2Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PXPress Release

www.shire.com

vendor

Related Shares:

Shire
FTSE 100 Latest
Value8,806.53
Change-16.38